RIPK3 and neoplasm: In fact, absence of RIPK3 in cancer cells is documented to reduce the type I IFNs-mediated immune responses following treatment with chemotherapy; such that, failure to induce necroptosis (due to lack of RIPK3 or MLKL) can hamper tumor-associated immune infiltration after chemotherapy [239].